javier pinilla-ibarz, md, phd: significance of treat to progression
Published 8 years ago • 66 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
0:45
javier pinilla-ibarz, md, phd: options to prolong survival
-
0:59
javier pinilla-ibarz, md, phd: principle treatment options for patients with a 17p deletion
-
1:08
javier pinilla-ibarz, md, phd - malignant hematology
-
1:12
javier pinilla-ibarz, md, phd: treatment options for patients with previously treated cll
-
0:47
javier pinilla-ibarz, md, phd: dose intensity
-
1:04
javier pinilla-ibarz, md, phd: additional chemo-immunotherapy
-
0:47
javier pinilla-ibarz, md, phd: relapse following purine analog therapy
-
1:48:40
fmipa ui webinar series 3
-
1:28:58
perturbative approaches to lss - lecture 1
-
2:45
cll treatment: which molecular tests will you need?
-
0:31
javier pinilla-ibarz, md, phd: phase iii data to support usage of bruton's tkis
-
0:42
javier pinilla-ibarz, md, phd: bendamustine/rituximab therapy
-
0:59
javier pinilla-ibarz, md, phd: use of bruton's tyrosine kinase inhibitor
-
1:48
dr. pinilla-ibarz on the role of chemotherapy in cll
-
0:52
dr. pinilla-ibarz discusses advancements in cml
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
1:14
dr. pinilla-ibarz on the impact of venetoclax in cll
-
1:24
how ibrutinib has transformed the treatment paradigm of cll
-
9:48
optimal combination and sequence of chronic lymphocytic leukemia therapies
-
5:06
treatment-free remission in cml
-
4:30
cll: when to initiate frontline therapy
-
9:21
relapse after cml treatment discontinuation